로딩 중…
지수 로딩 중…
한국파마
032300· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩7,790+6.57%
2026-08-04
Financials
Valuation Metrics
한국파마's Market Cap is ₩850B. At end of 2025 it was ₩1418B. Ranked #1353 of 2,436 in KR market (top 56%), #751 of 1,649 on KOSDAQ (top 46%), #147 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 63%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 84.96B KRW | KR#1,353/2,436 Sec#147/234 |
| Revenue | 91.42B KRW | KR#1,444/2,436 Sec#89/234 |
| Net Income | -2.47B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 129.97B KRW | KR#1,568/2,436 Sec#126/234 |
| Net Assets | 68.93B KRW | KR#1,654/2,436 Sec#142/234 |
| Employees | 284 | KR#826/2,436 Sec#69/234 |
| Value | ||
| P/B | 1.23x | KR#1,663/2,436 Sec#113/234 |
| P/S | 0.93x | KR#1,347/2,436 Sec#77/234 |
| FCF Yield | 1.69% | KR#1,093/2,436 Sec#75/234 |
| Profitability | ||
| ROE | -3.59% | KR#1,698/2,436 Sec#122/234 |
| ROA | -1.90% | KR#1,693/2,436 Sec#121/234 |
| Op. Margin | -0.45% | KR#1,635/2,436 Sec#117/234 |
| Revenue Growth | 18.36% | KR#678/2,436 Sec#65/234 |
| Earnings Growth | 32.60% | KR#672/2,436 Sec#42/234 |
| Financial Health | ||
| Debt Ratio | 188.54% | KR#1,616/2,436 Sec#183/234 |
| Total Debt | 38.42B KRW | KR#1,089/2,436 Sec#80/234 |
| FCF | 1.44B KRW | KR#1,118/2,436 Sec#81/234 |
| Cash | 29.45B KRW | KR#1,019/2,436 Sec#67/234 |
| Current Ratio | 1.14x | KR#1,664/2,436 Sec#170/234 |
| Dividend | ||
| Div. Yield | 0.68% | KR#1,238/2,436 Sec#78/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -46.35% | KR#1,993/2,436 Sec#184/234 |
| 1M Return | -4.42% | KR#1,343/2,436 Sec#137/234 |
| From 52W High | -48.44% | KR#1,123/2,436 Sec#95/234 |
| 1Y MDD | -55.87% | KR#1,201/2,436 Sec#97/234 |
| Trading | ||
| Volume | 14,229 shares | KR#2,007/2,436 Sec#201/234 |
| Foreign Own. | 0.99% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -227 KRW | KR—/2,436 Sec—/234 |
| BPS | 6,320 KRW | KR#1,265/2,436 Sec#90/234 |
Company Info
동사는 1974년 민생제약사 인수, 1985년 법인 전환 후 의약품 제조 및 판매를 주요 사업으로 하고 있음. 자체 R&D로 정신신경계, 순환기계, 소화기계, 항생항균 등에 강점이 있으며, 다양한 질환군의 처방 의약품을 제조 및 판매하고 있음. 2018년 신약연구센터 개소, 2021년 연구환경을 개선하고 차별화 제품 발굴, 제네릭에서 신약까지 개발을 확장하고 있음. 한국파마는 1985년에 설립되었으며 경기도 화성시에 본사를 두고 있습니다.